VALGENT: A protocol for clinical validation of human papillomavirus assays.
about
Comparison of Two Widely Used Human Papillomavirus Detection and Genotyping Methods, GP5+/6+-Based PCR Followed by Reverse Line Blot Hybridization and Multiplex Type-Specific E7-Based PCR.Performance of a Cartridge-Based Assay for Detection of Clinically Significant Human Papillomavirus (HPV) Infection: Lessons from VALGENT (Validation of HPV Genotyping Tests)Diagnostic accuracy of high-risk HPV DNA genotyping for primary cervical cancer screening and triage of HPV-positive women, compared to cytology: preliminary results of the PIPAVIR study.Evaluation of the Clinical Performance of the HPV-Risk Assay Using the VALGENT-3 Panel.A comparison of the MeltPro® HPV Test with the Cobas® HPV Test for detecting and genotyping 14 high-risk human papillomavirus types.Evaluation of a Novel Single-Tube Method for Extended Genotyping of Human Papillomavirus.Human papillomavirus E7 protein detection as a method of triage to colposcopy of HPV positive women, in comparison to genotyping and cytology. Final results of the PIPAVIR study.HPV genotype-specific concordance between EuroArray HPV, Anyplex II HPV28 and Linear Array HPV Genotyping test in Australian cervical samples.Clinical validation of REALQUALITY RQ-HPV Screen according to the international guidelines for human papillomavirus DNA test requirements for cervical screening.Validation of a Human Papillomavirus (HPV) DNA Cervical Screening Test That Provides Expanded HPV Typing.Comparison of the Cepheid Xpert HPV test and the HC2 High-Risk HPV DNA Test for detection of high-risk HPV infection in cervical smear samples in SurePath preservative fluid.Validation of intra- and inter-laboratory reproducibility of the Xpert HPV assay according to the international guidelines for cervical cancer screeningThe new screening program to prevent cervical cancer using HPV DNA: getting the balance right in maintaining qualityClinical Evaluation of INNO-LiPA HPV Genotyping II Assay Using the VALGENT Framework
P2860
Q37132091-5137B921-FCC6-4262-993F-7C8D2BE44668Q37218644-2A4B0410-185B-463B-A6A0-F94F5CBA80CDQ40280339-7160A41A-A644-4511-AB08-3A56D9D2AF47Q47097439-F3705741-0C32-4E3C-BAD1-57B8D7B76F34Q47280015-71FA3C0F-F7E2-4C20-B1F4-01825EBA2744Q47315433-F6BD8846-78B9-42B7-9DA4-C2E297DBB571Q47790765-F5F6BED3-8F59-40A8-BEC2-AA059B06E4A1Q49591665-6FEDBB7D-5560-4A8C-87BB-32ECDE0DD653Q52646463-C6905452-667D-41C3-B810-0CA3623689AFQ52680864-AFE4BB1F-85FA-490E-89D8-E6144B67309FQ53176728-E949037C-9FF3-4889-B9E2-C99B3FCBB5C0Q58107919-22F2FB6E-19D1-4D88-9970-77ACD065E619Q58749274-A2849712-1FB2-465C-9F89-43F5A3BA2B3DQ58749448-4798BDB0-F9D7-4F6E-B41A-37A31A646DFE
P2860
VALGENT: A protocol for clinical validation of human papillomavirus assays.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
VALGENT: A protocol for clinical validation of human papillomavirus assays.
@en
type
label
VALGENT: A protocol for clinical validation of human papillomavirus assays.
@en
prefLabel
VALGENT: A protocol for clinical validation of human papillomavirus assays.
@en
P2093
P50
P1476
VALGENT: A protocol for clinical validation of human papillomavirus assays
@en
P2093
Daan Geraets
Isabelle Heard
Kate Cuschieri
Marc Arbyn
Mario Poljak
Markus Schmitt
Massimo Tommasino
Tarik Gheit
P304
P356
10.1016/J.JCV.2015.09.014
P478
76 Suppl 1
P577
2015-10-08T00:00:00Z